For a Jehovah's Witness patient with multiple myeloma, could you safely offer a BCMA-directed bispecific antibody or CAR-T therapy?

Short answer is - yes! Long answer is - it depends.

Patients can be optimized leading into CAR T-cell therapy by using ESAs and possible TPO agonists, iron, B12, folate supplementation. The main issue is around propensity for anemia and thrombocytopenia, especially if profound and prolonged. Patient...

Jehovah's Witness patients can be under-treated or receive inappropriate care within medical systems because of their views about transfusions. Many of these patients refuse red blood cell or platelet transfusions, but allow for autologous stem cells.

From a clinician standpoint, what is the differe...